# Drugs
**-fibr-**
- **[[Gemfibrozil]]**
- **[[Fenofibrate]]**, [[Bezafibrate]], etc.

# Mechanism of Action
**落 [[PPAR-α]]** →
- **↓ [[Triglycerides]]** -- **30-35%**
	- **↑↑ [[Metabolism of Lipids]]**
	- **落 [[Lipoprotein Lipase]]** → **↑ [[VLDL]] catabolism**
	- ↓ [[apoC-III]] → **↑ [[Lipolysis]]**
- ↓ [[LDL]] -- ~10-20%
	- ↑ affinity to [[LDL Receptor]]
	- ↑ [[LDL Receptor]]
- **↑ [[HDL]]** -- **15-20%**
	- ↑ [[ApoA-I]] and ↑ [[apoA-II]] expression

# Phamacokinetic
- High and ripid absorption → given q meal
- T1/2 q drugs
	- **[[Gemfibrozil]]** ~ 1 hr
	- **[[Fenofibrate]]** ~ 20 hr
- **Excrete via [[Kidney]]** ~ 60-90%

# Indication
- **[[Hypertriglyceridaemia]]**
- **[[Chylomicronaemia Syndrome]]**
- **[[Dysbetalipoproteinaemia]]**

# Side Effects
- **[[Rhabdomyolysis]]** and others [[Myopathy]] -- esp. [[Gemfibrozil]] c [[HMG-CoA Reductase Inhibitors]] ⊢ close [[CK]] monitoring and use [[Fenofibrate]]
- ↑ risk of [[Gallstone]] -- esp. [[Clofibrate]]
- Mild GI SEs and ↑ [[Liver Enzymes]] -- minor

# Contraindication
- **[[Renal Failure]]**
- [[Hepatic Failure]] and [[Pathology of Liver and Biliary System#Pathology of Biliary System|Biliary Diseases]] -- caution